|
Screening for glaucoma: comparative effectiveness |
Ervin AM, Boland MV, Myrowitz EH, Prince J, Hawkins B, Vollenweider D, Ward D, Suarez-Cuervo C, Robinson KA |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ervin AM, Boland MV, Myrowitz EH, Prince J, Hawkins B, Vollenweider D, Ward D, Suarez-Cuervo C, Robinson KA. Screening for glaucoma: comparative effectiveness. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 59. 2012 Authors' objectives Open-angle glaucoma (OAG) is the most common form of progressive optic neuropathy, and it is estimated that more than half of those who have glaucoma are undiagnosed. The objective of this review was to assess the effect of screening for OAG. We also summarized the accuracy of diagnostic tests. Authors' conclusions We did not identify any systematic review or study that provided evidence for direct or indirect links between glaucoma screening and visual field loss, visual impairment, optic nerve damage, intraocular pressure, or patient-reported outcomes. Early treatment is important in determining the indirect chain of evidence for screening; the treatment of glaucoma is addressed in the report Treatment for Glaucoma: Comparative Effectiveness. There have been improvements in screening devices, yet there is limited evidence on the effects of screening for
OAG. Indexing Status Subject indexing assigned by CRD MeSH Glaucoma, Open-Angles; Mass Screening Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32013000187 Date abstract record published 21/03/2013 |
|
|
|